All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Equity

ECM loses Capsugel IPO but gets Sfr3bn Lonza rights issue

Capsugel capsule 230x150

Another piece of next year’s equity capital markets issuance puzzle was turned over today, when Lonza, the Swiss pharmaceutical and chemical company, announced a Sfr3.3bn rights issue to pay for the acquisition of Capsugel from KKR.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree